NIH/NIDDK Phase I SBIR
Human induced pluripotent stem cell-derived beta-cells for drug and toxicity testing.
NIH/NIDDK Phase II SBIR
Follow-on proposal to our awarded NIH-SBIR Phase I application with the goal to optimize cell lines and scale up RMS ILCs platforms
NIH/NIDDK Phase 1 SBIR
Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem cells. Focus: MODY patient cell lines.
NIH/NIDDK Phase I SBIR
Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell function.
NIH/NIDDK Phase I SBIR
Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening applications.
WI SBIR Advance
Phase II matching grant to assist in commercialization.
NIH/NIDDK Phase I SBIR
Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells.
NIH/NIDDK Phase I SBIR
Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune tolerance